FDA revamps adverse event reporting guidance for Covid-19
The FDA on Thursday revised its guidance on postmarket adverse event reporting for medical products and dietary supplements during a pandemic to apply the guidance to the ongoing coronavirus disease (Covid-19) pandemic.
The guidance, which applies to drugs, biologics, medical devices, combination products and supplements, details how FDA intends to prioritize adverse event reporting requirements during a pandemic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.